Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -297.00K | $ -622.00K | $ -99.00K | $ -97.00K |
| Operating Income | $ -104.55M | $ -83.53M | $ -38.79M | $ -24.76M | $ -9.32M |
| EBITDA | $ -104.55M | $ -81.93M | $ -38.58M | $ -24.65M | $ -9.27M |
| Net Income | $ -89.02M | $ -71.58M | $ -37.75M | $ -24.72M | $ -18.93M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 313.44M | $ 253.15M | $ 75.54M | $ 110.02M | $ 130.37M |
| Total Assets | $ 325.76M | $ 271.87M | $ 83.30M | $ 113.33M | $ 131.00M |
| Total Debt | $ 0.00 | $ 335.00K | $ 323.00K | $ 159.00K | $ 105.00K |
| Net Debt | $ -124.12M | $ -99.81M | $ -75.21M | $ -109.86M | $ -130.26M |
| Total Liabilities | $ 15.91M | $ 25.96M | $ 160.12M | $ 156.22M | $ 151.31M |
| Stockholders' Equity | $ 309.85M | $ 245.91M | $ -76.83M | $ -42.89M | $ -20.30M |
| Cash Flow | |||||
| Free Cash Flow | $ -73.24M | $ -61.42M | $ -32.69M | $ -19.32M | $ -8.99M |
| Operating Cash Flow | $ -73.19M | $ -61.27M | $ -32.08M | $ -19.13M | $ -8.53M |
| Investing Cash Flow | $ -36.00M | $ -148.41M | $ -612.00K | $ -191.00K | $ -461.00K |
| Financing Cash Flow | $ 133.16M | $ 234.29M | $ -1.80M | $ -1.02M | $ 130.51M |